On Friday, Zix Corporation (NASDAQ:ZIXI)’s shares inclined 2.84% to $5.44.
Zix Corporation (ZIXI) has been on the move lately as the stock has risen by 12.6% in the past four weeks, and it is presently trading well above its 20-Day SMA.
While there can be no telling for sure, it is certainly encouraging that earnings estimates have risen in the past few weeks on the company, suggesting that sentiment on ZIXI is moving in the right direction. In fact, the stock presently has a Zacks Rank #2 (Buy), suggesting that the recent run could certainly continue for this in-focus company.
Zix Corporation provides email encryption, data loss prevention (DLP), and Bring-Your-Own-Device solutions to the healthcare, financial services, insurance, and government sectors in the United States. The company offers Zix Email Encryption, a software-as-a-service solution that allows an enterprise to use policy-driven rules to determine, which email messages should be sent securely to comply with regulations or company-defined policies.
Golar LNG Limited (USA) (NASDAQ:GLNG)’s shares gained 0.64% to $50.67.
Golar LNG Ltd. (GLNG) declared the formation of a 50/50 joint venture with Stolt-Nielsen Limited to pursue opportunities in small-scale LNG production and distribution. Stolt-Nielsen has also made a strategic investment in Golar through open market purchases, representing an ownership stake of approximately 2.3%.
The joint venture between Golar and Stolt-Nielsen will draw upon the logistics and small-scale LNG assets controlled by Stolt-Nielsen and the ocean-based LNG midstream assets controlled by Golar to provide a fully integrated LNG logistics service to consumers of natural gas.
Golar LNG Limited, a midstream liquefied natural gas (LNG) company, engages in the transportation, regasification, liquefaction, and trading of LNG. The company operates in three segments: Vessel Operations, LNG Trading, and FLNG. It is involved in the acquisition, ownership, operation, and chartering of LNG carriers and floating storage regasification units (FSRUs); and the development of LNG projects.
At the end of Friday’s trade, UBS Group AG (USA) (NYSE:UBS)‘s shares surged 0.80% to $21.42.
UBS Group AG (USA) (UBS) has taken another substantial step to improve the resolvability of the Group in response to regulatory requirements affecting the entire banking industry. UBS Switzerland AG is now operating as a fully-owned banking partner of UBS AG with its own banking license. As part of the changes to UBS’s legal structure, UBS AG’s Retail & Corporate and Wealth Administration businesses booked in Switzerland have been transferred to UBS Switzerland AG, effective June 14.
These changes will have no impact on UBS’s strategy or on the firm’s business, nor will they affect the way it serves the vast majority of the about 2.7 million clients of UBS Switzerland AG. UBS Group will continue to maintain its industry-leading capital position. UBS Switzerland AG has total assets of more than CHF 300 billion and more than 11,000 employees. As the leading bank in Switzerland, it remains an integral part of the UBS Group and its global franchise.
UBS Group AG, together with its auxiliaries, provides wealth administration, retail and corporate, asset administration, and investment banking products and services worldwide. The company’s Wealth Administration division provides financial services to wealthy private clients. This division offers investment administration solutions and wealth planning and corporate finance advisory services, in addition to a range of specific offerings. Its Wealth Administration Americas division provides advice-based solutions and banking services through financial advisors to ultra high net worth and high net worth individuals and families. This division operates domestic United States and Canadian business, in addition to international business booked in the United States.
Edwards Lifesciences Corp (NYSE:EW), ended its Friday’s trading session with 0.74% gain, and closed at $146.17.
Edwards Lifesciences Corp (EW) declared U.S. Food and Drug Administration (FDA) approval of its most advanced transcatheter aortic heart valve – the Edwards SAPIEN 3 valve with the Commander Delivery System – for the treatment of high-risk patients suffering from severe, symptomatic aortic stenosis.
Dr. Leon was the co-principal investigator for the PARTNER II Trial. SAPIEN 3 approval was based on a cohort of the PARTNER II Trial, which enrolled 583 high-risk patients at 29 U.S. sites.
The SAPIEN 3 valve builds on Edwards’ decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves. The new valve, accessible in 20mm, 23mm, 26mm and 29mm sizes, has an outer skirt – a cuff of fabric surrounding the valve frame – providing a seal to address paravalvular leak.
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
